Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00690066 · ClinicalTrials.gov registry record · Phase 2
PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)
A Phase 2 study of Type 1 Diabetes and Type 1 Diabetes Mellitus, sponsored by Mesoblast.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 20
- Study locations
NCT00690066: Completed Phase 2 study of Type 1 Diabetes and Type 1 Diabetes Mellitus, sponsored by Mesoblast.
NCT00690066 is a Phase 2 study of Type 1 Diabetes and Type 1 Diabetes Mellitus that has completed, run by Mesoblast. The registered enrollment target is 63 participants, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00690066, a Phase 2 study of Type 1 Diabetes and Type 1 Diabetes Mellitus, has completed, sponsored by Mesoblast.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to establish the safety and efficacy of multiple administrations of PROCHYMAL® in participants recently diagnosed with type 1 diabetes mellitus.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PROCHYMAL®
Study Locations (20)
California
- Scripps Whittier Diabetes Institute - La Jolla
- Stanford University - Stanford
Florida
- University of Florida - Gainesville
- Diabetes Research Institute - Miami
Nevada
- Desert Endocrinology CRC - Henderson
- Nevada Alliance Against Diabetes - Las Vegas
North Carolina
- University of North Carolina Diabetes Care Center - Chapel Hill
- American Health Research, Inc. - Charlotte
Ohio
- The Lindner Clinical Trial Center - Cincinnati
- Providence Health Partners - Center for Clinical Research - Dayton
Wisconsin
- University of Wisconsin Health- West Clinic - Madison
- Clinical and Transitional Science Institute - Milwaukee
Alabama
- University of Alabama, Division of Endocrinology & Metabolism - Birmingham
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2008-06-11 |
| Est. Completion | 2011-12-19 |
| Phase | Phase 2 |
What the finished NCT00690066 record still lists
NCT00690066 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (92% lower).
The record links to 4 conditions, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00690066 names 20 study sites across 14 states, led by California, Florida, Nevada.
Frequently Asked Questions
What is clinical trial NCT00690066 about?
NCT00690066 is a clinical study titled "PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)". The purpose of this study is to establish the safety and efficacy of multiple administrations of PROCHYMAL® in participants recently diagnosed with type 1 diabetes mellitus.
What is the current status of trial NCT00690066?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2008-06-11. Estimated completion is 2011-12-19.
What conditions does trial NCT00690066 study?
This clinical trial studies the following conditions: Type 1 Diabetes, Type 1 Diabetes Mellitus, Diabetes Mellitus, Insulin-Dependent, Juvenile Diabetes.
What interventions are being tested in trial NCT00690066?
The interventions under investigation include: Placebo (DRUG), PROCHYMAL® (DRUG).
Who is sponsoring clinical trial NCT00690066?
This trial is sponsored by Mesoblast, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00690066 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Kentucky, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00690066's enrollment target sits among peer trials
63 71st of 198 higher than 128 of 198 other Type 1 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Precision Administration of Anti-thymocyte Globulin With or Without Verapamil
RECRUITING · Phase 2
-
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
RECRUITING · Phase 2
-
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
RECRUITING · Phase 2
-
Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes
RECRUITING · Phase 2
-
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
RECRUITING · Phase 2
-
TArgeting Type 1 Diabetes Using POLyamines (TADPOL)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI